Diagnostic, Prognostic, and Therapeutic Implications of Genetic Testing for Hypertrophic Cardiomyopathy

J. Martijn Bos, Jeffrey Towbin, Michael J. Ackerman

Research output: Contribution to journalReview article

232 Citations (Scopus)

Abstract

Over the last 2 decades, the pathogenic basis for the most common heritable cardiovascular disease, hypertrophic cardiomyopathy (HCM), has been investigated extensively. Affecting approximately 1 in 500 individuals, HCM is the most common cause of sudden death in young athletes. In recent years, genomic medicine has been moving from the bench to the bedside throughout all medical disciplines including cardiology. Now, genomic medicine has entered clinical practice as it pertains to the evaluation and management of patients with HCM. The continuous research and discoveries of new HCM susceptibility genes, the growing amount of data from genotype-phenotype correlation studies, and the introduction of commercially available genetic tests for HCM make it essential that the modern-day cardiologist understand the diagnostic, prognostic, and therapeutic implications of HCM genetic testing.

Original languageEnglish (US)
Pages (from-to)201-211
Number of pages11
JournalJournal of the American College of Cardiology
Volume54
Issue number3
DOIs
StatePublished - Jul 14 2009
Externally publishedYes

Fingerprint

Hypertrophic Cardiomyopathy
Genetic Testing
Therapeutics
Medicine
Genetic Association Studies
Sudden Death
Cardiology
Athletes
Cause of Death
Cardiovascular Diseases
Research
Genes

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Diagnostic, Prognostic, and Therapeutic Implications of Genetic Testing for Hypertrophic Cardiomyopathy. / Bos, J. Martijn; Towbin, Jeffrey; Ackerman, Michael J.

In: Journal of the American College of Cardiology, Vol. 54, No. 3, 14.07.2009, p. 201-211.

Research output: Contribution to journalReview article

@article{73468ac508d749c481436207e4d8be5e,
title = "Diagnostic, Prognostic, and Therapeutic Implications of Genetic Testing for Hypertrophic Cardiomyopathy",
abstract = "Over the last 2 decades, the pathogenic basis for the most common heritable cardiovascular disease, hypertrophic cardiomyopathy (HCM), has been investigated extensively. Affecting approximately 1 in 500 individuals, HCM is the most common cause of sudden death in young athletes. In recent years, genomic medicine has been moving from the bench to the bedside throughout all medical disciplines including cardiology. Now, genomic medicine has entered clinical practice as it pertains to the evaluation and management of patients with HCM. The continuous research and discoveries of new HCM susceptibility genes, the growing amount of data from genotype-phenotype correlation studies, and the introduction of commercially available genetic tests for HCM make it essential that the modern-day cardiologist understand the diagnostic, prognostic, and therapeutic implications of HCM genetic testing.",
author = "Bos, {J. Martijn} and Jeffrey Towbin and Ackerman, {Michael J.}",
year = "2009",
month = "7",
day = "14",
doi = "10.1016/j.jacc.2009.02.075",
language = "English (US)",
volume = "54",
pages = "201--211",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Diagnostic, Prognostic, and Therapeutic Implications of Genetic Testing for Hypertrophic Cardiomyopathy

AU - Bos, J. Martijn

AU - Towbin, Jeffrey

AU - Ackerman, Michael J.

PY - 2009/7/14

Y1 - 2009/7/14

N2 - Over the last 2 decades, the pathogenic basis for the most common heritable cardiovascular disease, hypertrophic cardiomyopathy (HCM), has been investigated extensively. Affecting approximately 1 in 500 individuals, HCM is the most common cause of sudden death in young athletes. In recent years, genomic medicine has been moving from the bench to the bedside throughout all medical disciplines including cardiology. Now, genomic medicine has entered clinical practice as it pertains to the evaluation and management of patients with HCM. The continuous research and discoveries of new HCM susceptibility genes, the growing amount of data from genotype-phenotype correlation studies, and the introduction of commercially available genetic tests for HCM make it essential that the modern-day cardiologist understand the diagnostic, prognostic, and therapeutic implications of HCM genetic testing.

AB - Over the last 2 decades, the pathogenic basis for the most common heritable cardiovascular disease, hypertrophic cardiomyopathy (HCM), has been investigated extensively. Affecting approximately 1 in 500 individuals, HCM is the most common cause of sudden death in young athletes. In recent years, genomic medicine has been moving from the bench to the bedside throughout all medical disciplines including cardiology. Now, genomic medicine has entered clinical practice as it pertains to the evaluation and management of patients with HCM. The continuous research and discoveries of new HCM susceptibility genes, the growing amount of data from genotype-phenotype correlation studies, and the introduction of commercially available genetic tests for HCM make it essential that the modern-day cardiologist understand the diagnostic, prognostic, and therapeutic implications of HCM genetic testing.

UR - http://www.scopus.com/inward/record.url?scp=67649854428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649854428&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2009.02.075

DO - 10.1016/j.jacc.2009.02.075

M3 - Review article

VL - 54

SP - 201

EP - 211

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 3

ER -